Risk Assessment of Neutropenia Based on Exposure Information Without Plasma Concentration Measurement in Pemetrexed–Platinum-Based Chemotherapy: A Modeling Approach Using Real-World Clinical Data

Background/Objectives: Pemetrexed–platinum chemotherapy is a key treatment option for non-squamous non-small cell lung cancer (NSCLC); however, its use is often limited by hematologic toxicity, particularly neutropenia. We aimed to develop a model-informed framework for assessing neutrophil dynamics using routinely available clinical data and pemetrexed exposure.